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Abstract: Iron is necessary for the normal development of multiple vital processes. Iron 
deficiency (ID) may be caused by several diseases, even by physiological situations that increase 
requirements for this mineral. One of its possible causes is a poor dietary iron intake, which is 
infrequent in developed countries, but quite common in developing areas. In these countries, 
dietary ID is highly prevalent and comprises a real public health problem and a challenge for 
health authorities. ID, with or without anemia, can cause important symptoms that are not 
only physical, but can also include a decreased intellectual performance. All this, together 
with a high prevalence, can even have negative implications for a community’s economic and 
social development. Treatment consists of iron supplements. Prevention of ID obviously lies 
in increasing the dietary intake of iron, which can be difficult in developing countries. In these 
regions, foods with greater iron content are scarce, and attempts are made to compensate this 
by fortifying staple foods with iron. The effectiveness of this strategy is endorsed by multiple 
studies. On the other hand, in developed countries, ID with or without anemia is nearly always 
associated with diseases that trigger a negative balance between iron absorption and loss. Its 
management will be based on the treatment of underlying diseases, as well as on oral iron 
supplements, although these latter are limited by their tolerance and low potency, which on 
occasions may compel a change to intravenous administration. Iron deficiency has a series of 
peculiarities in pediatric patients, in the elderly, in pregnant women, and in patients with dietary 
restrictions, such as celiac disease.
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Introduction
Iron is highly important for human beings, since it is involved in multiple processes 
of cell energy metabolism, in which its presence is essential. However, an excess of 
this metal is very harmful. Both reasons explain its very finely regulated metabolism, 
as it achieves a rather narrow balance. Perhaps because an organism does not have a 
physiological means for eliminating the excess of remaining iron, its intestinal absorption 
is low, similar to its physiological losses, and iron can increase only slightly, even in 
cases of deficiency. This accounts for the frequent development of iron deficiency (ID) 
when there are concomitant factors that increase its losses or requirements, or when its 
intake decreases. Regardless of its etiology, the World Health Organization (WHO) 
estimates that anemia affects over 1.62 billion people worldwide. The most affected 
group is preschool-age children, with a prevalence of 47%, followed by pregnant women 
(41%), non-pregnant women (30%), school-age children (25%), and people older than 
60 years of age (24%); men are the least affected group (12%). However, globally, the International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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most numerous population group is non-pregnant women 
(468.4 million). In terms of geographical distribution, the most 
affected regions in all studied groups are Africa and South 
East Asia, while the least affected areas are Europe and the 
Western Pacific.1 According to WHO data, the frequency of 
ID in developing countries is 2–5 times greater than that of 
iron deficiency anemia (IDA), due to various factors, such as 
infections and malnutrition. In light of all this information, 
the importance of ID worldwide in the twenty-first century 
is evident.
Next, we will review some of the most important aspects 
of ID, or IDA, focusing primarily on their treatment, and, 
more specifically, when the etiology is an inadequate iron 
intake.
Metabolism of iron, etiopathogenesis, 
and development of ID and IDA
Iron is the most abundant trace element in humans. Its main 
role, but not the only one, is to form part of hemoglobin, 
an essential protein for oxygen transport. Moreover, it mediates 
other chemical reactions that are critical for life, forming 
part of the enzymes implicated in DNA synthesis and cell 
respiration. These physiological roles are carried out due to its 
ability to uptake and donate electrons, interchanging between 
its ferric (Fe3+) and ferrous (Fe2+) forms. For similar reasons, 
it can also be very toxic for tissues, as it intervenes in the 
formation of free radicals. Therefore, its metabolism is very 
finely regulated and practically all the iron in our body is bound 
to proteins. The average daily dietary iron intake in developed 
countries is between 10 and 15 mg;2 under normal conditions, 
only between 5% and 10% of this quantity is absorbed, that 
is, 1–3 mg/day. This absorption takes place primarily in the 
duodenum and proximal jejunum, and it is complex and highly 
regulated, as the key point in iron metabolism. Dietary iron 
can be found in two forms: heme iron and non-heme iron. 
Heme iron is contained in hemoglobin or myoglobin, and 
is derived almost exclusively from meat (veal, pork, lamb, 
chicken, turkey, and others), fish, and seafood. Non-heme iron 
(especially ferric salts) is most frequently found in vegetables 
(legumes, corn, wheat, barley, and others), but also in animal-
source foods, iron-fortified foods such as rice, pasta, bread, 
and other cereals, cooked spinach, nuts, seeds and dry fruits, 
eggs, and dairy products. The absorption of iron in these two 
forms is different. Heme iron has a greater bioavailability, 
with absorption of 20%–30%. Thus, once the heme group 
of proteins containing it is released, it remains soluble and is 
taken up easily, although by a mechanism not entirely known. 
Non-heme iron, the most abundant in the diet, can be found 
either reduced or oxidized. Facilitated by gastric acidity, iron 
in oxidized form is reduced (Fe++) by an enzyme present in the 
enterocyte brush border, being absorbed at a rate of less than 
10%. This absorption is maximized by ascorbic acid and foods 
with a substantial content of heme iron, but is inhibited by 
calcium, phytates, and polyphenols. Table 1 shows the amounts 
of iron in different foods. Enterocytes are the key element in 
this absorption process. Iron, in its reduced form, enters the 
enterocyte cytoplasm by means of a membrane transporter. 
At least three main mechanisms have been identified in the 
regulation of this absorption process. The most important is 
erythropoietic requirements, in such a way that absorption 
increases with increasing requirements. Thus, in anemic 
individuals, absorption increases, although up to no more than 
20–40 mg/day.3 The second mechanism is dietary iron content, 
so that absorption decreases as dietary content increases. 
The third main mechanism is a reduction in the iron pool, 
which increases its absorption. Once absorbed and inside the 
enterocyte, iron moves on to the plasma and, transported by 
transferrin, reaches the cells where it will be used, especially 
in erythropoietic precursor cells in bone marrow. The uptake of 
iron-transferrin complexes in all these cells is a process that is 
also mediated by receptors, resulting in the intra-cytoplasmic 
release of iron. Once in cytoplasm, in hematopoietic cells, 
Table 1 Iron content of different foods
Iron (mg)
Foods that contain iron bound to a heme group:  
75 g of “cooked” food (meat, fish, shellfish, poultry)
Clams 21
Liver, pork 13.4
Liver, chicken 8.7
Oysters 6.4
Mussels 5
Liver, veal 4.9
veal 2.4
Shrimp 2.3
Sardines 2
Lamb 1.5
Foods that contain iron not 
bound to a heme group
Usual daily amount
Pumpkin (seeds, roots, cooked) 60 mL (1/4 glass) 8.6
“Cured” or “semicured” tofu  
(soy cheese)
150 g (3/4 glass) 2.4–8
Children’s cereals (dry) 28 g 6–7
Soybeans, dry, cooked 175 mL (3/4 glass) 6.5
Instant fortified flour 1 packet 4.2–6
Lentils, cooked 175 mL (3/4 glass) 4.9
Cold fortified cereals 30 g 4
Red beans, cooked 175 mL (3/4 glass) 3.9
Molasses 15 mL 3.6
Refried beans 175 mL (3/4 glass) 3.1International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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iron enters the mitochondria to participate in the synthesis of 
the heme group, an essential component of hemoglobin. In 
the remaining cells, it can mediate other metabolic processes 
(eg, synthesis of myoglobin or some enzymes such as 
catalases and peroxidases) or be stored in the form of ferritin 
or hemosiderin, to be used when necessary. Ferritin, present 
especially in the liver, stores iron in a soluble, mobilizable 
way, whereas hemosiderin, mainly located in the smooth 
endoplasmic reticulum, stores non-mobilizable iron. Another 
key molecule in iron metabolism is hepcidin, a hepatocyte-
produced peptide hormone that modulates the passing of iron 
from cells (enterocytes, macrophages, and hepatocytes) to 
the plasma.4
From a pathogenetic standpoint, we can classify the 
causes of ID/IDA into two groups: those involving a reduced 
intake, and those involving increased losses. Furthermore, 
some physiological situations can increase the body’s iron 
requirements, promoting its deficiency, for example, periods 
of rapid growth, pregnancy, and reproductive age in women 
(menstrual losses). Table 2 summarizes the recommended 
daily amounts of iron by age and gender.5 The relative fre-
quency of different etiologies of ID and IDA depends on these 
factors (see Table 3). However, globally, the most influential 
aspect is the degree of economic development of the analyzed 
population. In developed countries, ID and IDA will be a 
consequence mainly of conditions that increase iron losses 
(any medical condition that involves bleeding) or, to a lesser 
extent, of disorders that cause a decreased absorption (eg, 
celiac disease) or perhaps even gastritis due to Helicobacter 
pylori, the likely origin of ID/IDA refractory to oral iron 
supplementation, which usually reverts once the germ has 
been eradicated, even without adding oral iron,6 or both pro-
cesses jointly. In our setting, insufficient dietary iron intake, 
a consequence either of overall malnutrition or specific dietary 
habits (eg, in strict vegetarians), is   usually not a cause of ID 
or IDA. Childhood and adolescence, women in childbearing 
age, and pregnancy are situations in which the prevalence of 
ID and IDA is much higher and is not always accompanied 
by pathologies. In the elderly, some physiological changes 
are present that also make the development of ID and IDA 
more likely; nonetheless, these changes do not justify their 
development and the investigation of other very relevant 
etiologies is required. In developing countries, the situation 
is very different. In this case, malnutrition and a poor dietary 
iron intake are very common and are frequently the cause of 
Table 2 Daily recommended amount of iron (mg) by gender 
and age
Males Adult 8 mg
Females .50 years 8 mg
19–50 years 18 mg
Pregnant 27 mg
Breastfeeding 9–10 mg
Adolescents (9–18 years) Female 8–15 mg
Male 8–11 mg
Children (0–8 years) 4–8 years 10 mg
1–3 years 7 mg
7 months–1 year 11 mg
0–6 months 0.27 mg
Table 3 Causes of iron deficiency or iron deficiency anemia
Gastrointestinal disorder  
with increased iron losses
Cancer/polyp: colon, stomach, 
esophagus, small bowel 
Peptic ulcer, esophagitis 
NSAID use 
Inflammatory bowel disease: 
ulcerative colitis, Crohn’s disease 
Intestinal parasites 
vascular lesions: angiodysplasia, 
watermelon stomach 
Meckel’s diverticulum
Gastrointestinal disorders  
that reduce iron absorption
Celiac disease 
Bacterial overgrowth 
whipple’s disease 
Lymphangiectasia 
Gastrectomy (partial and total) 
and gastric atrophy 
Gut resection or bypass
Urological and gynecological  
disorders
Menorrhagia 
Hematuria 
Chronic renal failure
Intravascular hemolysis Prosthetic valves and cardiac 
myxomas 
Paroxysmal nocturnal 
hemoglobinuria 
Marathon runners 
Multiple blood donations
Deficient intake Low socioeconomic class 
vegetarian diets 
Dissociated diets 
Alcoholism 
elderly patients 
High-risk ethnic groups
Medication that reduces  
gastric acid or iron affinity
Dietary factors 
Tannin 
Phytates in fiber 
Calcium in milk 
Tea 
Coffee
Increased requirements in  
various stages of life
Infants up to 3 years and 
adolescents 
Pregnant women 
Breastfeeding women 
Multiparous 
Post-partum
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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ID or IDA. Coexistence of other factors is   common in the 
genesis of ID, such as intestinal parasites.
Consequences of iron deficiency in 
humans
Iron deficiency has a great impact on the organism involved, 
as it interferes in all the reactions in which iron is involved. 
This will eventually result in well-known clinical conse-
quences. The clinical presentation varies greatly from one 
case to the next, depending on the rapidity of onset of anemia, 
its severity, and the characteristics of the patient suffering 
from it. The cause of ID/IDA is another influencing factor, as 
well as the existence of other added nutritional deficiencies, 
or even a protein-calorie malnutrition. Thus, IDA or ID can 
be detected in subjects that are asymptomatic or when they 
present with systemic symptoms, more or less important, 
such as weakness, tiredness, irritability, lack of concentration, 
  headache, intolerance to exercise, or even a clinical presen-
tation of heart failure in more serious cases. Some patients 
with ID, with or without anemia, can experience alopecia, 
atrophy of lingual papillae, or dry mouth due to decreased 
salivation. Other types of symptomatology, such as frailty 
of nails or spoon nails (koilonychia), chlorosis, or Plummer-
Vinson or Paterson-Kelly syndromes (with dysphagia due to 
esophageal membranes and atrophic glossitis) have practi-
cally   disappeared. The most dramatic consequences of ID 
are increases in both maternal and prenatal/perinatal mor-
tality, apart from an increase in prematurity. In fact, 40% of 
perinatal maternal deaths are associated with anemia.7 Iron 
deficiency has also been shown to impair cognitive perfor-
mance and physical abilities, thus affecting performance at 
school and work.8,9 The immune system is also affected by 
several mechanisms that influence the correct functioning 
of leukocytes,6 thus increasing morbidity from infectious 
diseases. Thyroid function can be affected by various mecha-
nisms that finally result in a reduction in triiodothyronine and 
an increase in thyroid peroxidase activity.10
It is important to point out that not only IDA, but also 
“simple” ID can cause symptoms, as has been shown in several 
studies. Furthermore, it is necessary to outline that some of 
these consequences are hardly quantifiable. Hence, ID has 
a clear negative impact on the quality of life of people who 
suffer it, in spite of not being easy to estimate this correctly. 
It is even more complicated to analyze other effects it most 
surely produces. We are referring here to its impact on school 
and work performance as well as its economic implications 
for patients and society. It is highly possible that the devel-
opment of human beings under   conditions of ID results in a 
lower intellectual and educational   development that, in the 
long term, will adversely influence their professional future 
and derived income. It could even be one of the reasons for 
slow development in poorer countries, hindering the adequate 
development of its human capital. Moreover, let us not forget 
that, in the event of ID in diet, there will most certainly be 
other deficiencies that will also have a negative impact on 
the adequate development of individuals. This is especially 
important in certain restrictive diets (either   medically or not 
medically indicated), since some diets have an evident indica-
tion for health purposes, such as gluten-free diets for celiac 
people, allergy diets, ketogenic diets in the management of 
metabolic disorders, and nutritional support diets in specific 
conditions affecting the gastrointestinal tract (eg, postopera-
tive patients); thus, it is not rare to identify calcium, zinc, 
tiamine, riboflavine, niacin, and folate deficiencies in these 
kinds of diets/patients.11
Diagnosis of ID and IDA
ID is defined as a decrease in total iron levels (both in 
serum and deposits), regardless of clinical expression. 
When the deficiency impairs erythropoiesis, it may result 
in a decrease in hemoglobin, with subsequent development 
of IDA. The diagnosis of anemia is simple and objective: the 
WHO defines it as a decline in blood hemoglobin to a level 
less than 13 g/dL in men and 12 g/dL in women. However, 
confirming that ID is the mechanism responsible for this 
anemia is not always easy. Sometimes, a simple blood cell 
count strongly suggests this origin, with a typical pattern 
of microcytosis, hypochromia, and an elevated red cell 
distribution width (RDW). However, up to 40% of cases of 
“pure” IDA are normocytic. The next step in assessing anemia 
is to determine the so-called iron metabolism. A typical 
pattern of ID is a decrease in sideremia, plasma ferritin, 
and transferrin saturation. The least reliable parameter for 
diagnosis of ID is probably the measurement of sideremia 
(total amount of iron bound to serum proteins), as it could 
be detected as an artifact due to contamination of laboratory 
equipment, shows a nocturnal rhythm, and can return to 
normal levels several hours after ingestion. In the absence of 
inflammation, serum ferritin reflects total iron deposits in the 
body. Thus, a low serum ferritin (,30 ng/L) unequivocally 
means ID. Transferrin saturation is especially useful when 
the measurement of ferritin is equivocal; a percentage of 
transferrin less than 20% implies ID.12 Zinc protoporphyrin is 
another indicator of IDA and early iron depletion. When iron 
supply is diminished, zinc utilization increases resulting in a 
high zinc protoporphyrin.13 Once it has been established that International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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ID is the cause of anemia, the next step is to diagnose why 
ID is present. Differential diagnosis will take into account the 
most frequent etiologies in each clinical scenario.
General management of ID and IDA 
anemia due to poor dietary intake
In a simplistic manner, when ID or IDA due to poor iron intake 
is present, the mainstay of its treatment and prevention is to 
normalize the amount of dietary iron. The problem is that this 
is not so easy in most patients under these circumstances, as it 
involves an economic effort they may not undertake. Having 
said this, we will take a graphical overview of what should 
be the general management in these cases, and later we will 
comment on the particularities of some specific situations. 
Of course, if another etiology associated with an inadequate 
dietary iron intake is evidenced when investigating the cause 
of anemia, it should be treated specifically.
Iron supplementation
The first measure in initial treatment is to provide iron supple-
ments until the values of hemoglobin and iron deposits have 
been normalized. This will usually be achieved by adminis-
tering iron orally.14 Even though it is broadly recommended 
to take it before breakfast in order to increase its absorption, 
there is no evidence supporting this, and it does significantly 
reduce tolerance; thus, it seems reasonable to administer it 
with foods (Table 4). One tablet of any commercially available 
preparation of ferrous salts provides more iron than intestines 
are able to absorb in 1 day. All ferrous salts (fumarate, lactate, 
succinate, glutamate, or sulfate) have similar   bioavailability. 
Iron glycinate preparations are a therapeutic alternative due 
to excellent bioavailability and lower frequency of side 
effects, such as constipation.15,16 Other formulations (several 
complexes of iron and proteins) may serve as substitutes for 
ferrous salts, but there is no strong evidence (from controlled 
clinical trials) showing these preparations are superior in 
terms of tolerance or clinical response. The treatment with 
oral iron is slow in reaching its goals, and a good compli-
ance is necessary to be   successful. The   therapeutic goals are 
recovery from anemia and   normalization of iron deposits. 
In any case, oral iron has important limitations. Often, the 
anemia is severe, and a quick response is needed. In other 
occasions, tolerance is poor, even following the precau-
tions we have recommended, and this is especially frequent 
in chronic bowel inflammatory disease. Finally, in other 
patients, it may not be intrinsically effective due to a problem 
of inadequate absorption, or because losses are greater than 
the limited capacity of oral assimilation. In these situations 
(poor tolerance, inadequate compliance, ineffectiveness, 
or clinical emergency), the use of parenteral iron is fully 
justified.14 The efficacy and safety of iron sucrose have been 
demonstrated in clinical trials and have been confirmed by 
broad practical experience.17 The only inconvenience with 
iron sucrose is that the infusion of several doses is necessary 
in order to provide the total required dose. More recently, new 
formulations such as carboxymaltose iron18 have appeared, 
making it possible to provide the entire required dose in 
just one or two sessions. In order to calculate the amount 
of iron a patient needs, a formula is used: Total iron defi-
ciency (mg) = [weight (kg) × (target Hb − specific patient’s 
Hb (g/L) × 0.24) + 500 (approximate deposits), where Hb 
is hemoglobin and 0.24 is a constant. Side effects are very 
uncommon and nearly always mild, except for extremely 
uncommon anaphylactoid (pseudoallergic) reactions; none-
theless, observation and measuring of vital signs during the 
administration of the infusion are required.
Dietary improvement
Secondly, in order to prevent the new development of ID 
or IDA, it is necessary to correct the patient’s diet. This is 
not always easy, especially in developing countries, due to 
economic determinants. The daily requirements of iron are 
1–3 mg/day; these requirements increase during the growth 
period, in women of childbearing age, and in pregnant 
women, and decrease due to the cessation of menses. 
Because gastrointestinal absorption of iron is limited, 
the diet must contain between 15 and 30 mg/day. Food-
frequency questionnaires combined with information on meal 
composition and food consumption patterns are necessary 
to analyze the amount of iron ingested by a person.7 Several 
kinds of questionnaires in multiple clinical scenarios have 
been used to assess the quantity of daily iron intake; readers 
are encouraged to consult some especially interesting articles 
relating to such questionnaires.19–21
The primary goal of dietary modification, that is, improving 
and maintaining the iron status of a population, involves 
changes in behavior, leading to an increase in the selection of 
Table 4 Recommendations for the use of oral iron
Initially use ferrous sulfate (if there is intolerance, assess other 
preparations)
Use doses that are not high (one tablet daily of any commercially 
available ferrous sulfate or of any other type of iron)
Administration after the main meal, perhaps accompanied by a glass  
of vitamin C-rich juice
Constancy until the full replenishment of depositsInternational Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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iron-containing foods and a meal pattern that favors increased 
bioavailability. Efforts should be focused on promoting the 
access to iron-rich foods (eg, meat and organs from cattle, fowl, 
fish, and poultry, and non-animal foods such as legumes and 
green leafy vegetables) and foods that enhance iron absorption 
(some fruits, vegetables, and tubers). Recommendations 
should be adapted to regional and local variations in diet and 
the age groups concerned. In the specific case of populations 
following diets based on vegetable consumption with scarce 
meat intake, frequent in developing countries (and also in 
vegetarians), in which iron is non-heme, and hence, ID is more 
likely,22 absorption may be increased by promoting the intake 
of foods that favor this, such as vitamin C,23,24 and avoiding 
those that hinder it, such as calcium, very fatty foods, phytates, 
and others.25 Table 5 shows some of these considerations in 
greater detail.
Iron fortification
Another approach to improve ID in large populations is food 
fortification. Iron fortification is a practical and cost-effective 
long-term solution to control ID on a nationwide scale. A pro-
gram of effective iron fortification mandates cooperation 
efforts among governments, food industry, and consumers. 
Iron fortification of foods is more difficult than fortification 
with other nutrients, such as iodine in salt. Iron compounds that 
are more soluble and absorbable, such as ferrous sulfate, often 
react with other ingredients in food, oxidize fats, and produce 
an unpleasant taste and color changes. Hence, other iron com-
pounds are used, such as ferric pyrophosphate, or electrolytic 
iron, and the amount required is twice that of ferrous sulfate, 
as they are less absorbable in the gastrointestinal tract, but 
they produce no sensory changes in foods.22,26,27 In any case, 
the appearance of these sensory changes should be monitored 
during the processing, storage, and preparation of foods. 
Moreover, it is necessary to identify an appropriate alimentary 
vehicle that reaches the entire target population, such as rice, 
pasta, or bread. Foods that are used most frequently in the 
fortification of populations are flours of staple cereals.
Several fortifiers have been used successfully in nation-
wide programs in different countries, and no significant 
side effects have been described with this fortification. In a 
meta-analysis of studies carried out in children receiving iron-
fortified foods, no adverse effects occurred and a protective 
effect against the development of respiratory infections was 
observed with fortification.27 It becomes necessary to use 
specific laboratory parameters relating to iron levels (such as 
ferritin or erythrocytic protoporphyrin) to evaluate the forti-
fication needs in a population and to monitor subsequently 
the results of such intervention.
ID and IDA in specific populations
ID in pediatric population
Iron requirements are particularly high during periods of rapid 
growth such as childhood,5 resulting in stages of high risk 
for ID. The first period ranges from 6 to 12 months of age, 
a period characterized by a certain imbalance between provi-
sions (continuation formulas with different proportions of iron 
fortification, introduction of different foods at unequal rhythms 
and amounts) and requirements (Table 2). The second period 
includes the entire duration of breastfeeding (1–3 years).
The high prevalence of IDA in childhood at the beginning of 
the twentieth century in the United States made this condition 
acquire the relevance of a public health problem. The strategy 
of universal screening, together with the promotion of breast-
feeding, the generalization of iron supplementation in artificial 
formulas and cereals, as well as the creation of a specific 
program in 1972 (WIC. “Special Supplemental Food Program 
for Women, Infants, and Children”) that included education, 
oriented both to professionals and the general population, had a 
very positive impact; thus, in the 1980s, the prevalence of IDA 
was reduced dramatically in the entire socioeconomic spectrum 
of the United States.28 This success turned screening into an 
approach restricted only to high-risk populations.
On the other hand, IDA is associated with the development 
of mental, motor, and behavioral changes in pediatric patients. 
The brain has a homeostasis mechanism to protect itself from 
both iron depletion and overload.29 Iron is heterogeneously 
distributed in the brain, with higher levels in white matter 
than in grey matter. It appears that neurons and glia cells 
Table 5 Nutritional strategy to avoid dietary iron deficiency
Increase the dietary iron intake
Promote the consumption of foods rich in iron, especially heme, as 
present in meat, poultry, fish, and seafood
Optimize the absorption of dietary iron 
a. enhancers of iron absorption:
Ascorbic acid or vitamin C (present in fruits, juices, potatoes and some 
other tubers, and other vegetables such as green leaves, cauliflower, 
and cabbage) 
Some cooked, fermented or germinated foods and condiments, such 
as sauerkraut and soy sauce (they reduce the amount of phytates)
b. Inhibitors of iron absorption:
Foods with high inositol content 
Phytates, present in cereal bran, cereal grains, high-extraction flour, 
legumes, nuts, and seeds 
Iron-binding phenolic compounds (tannins); foods containing the most 
potent inhibitors and that are resistant to the influence of enhancers 
include tea, coffee, herbal infusions, and certain spices (eg, oregano) 
Calcium, particularly from milk and dairy productsInternational Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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accumulate iron via a transferrin-dependent mechanism. 
Inside cells, it is bound to proteins as an accumulation 
reserve (ferritin) or functional reserve (bound to enzymes). 
This dual pathway serves as a protection element against 
abrupt changes in iron serum levels within certain ranges.30 
A recent review has documented such alterations: a tendency 
to fail in school, worse mathematical calculation, worse 
results in comprehension and development of reading-writing 
skills, as well as lower scores in complex psychomotor 
tests.31 Moreover, there is a greater tendency to present with 
conflictive behavior with parents and teachers. Many of 
these deficiencies or alterations can be corrected with iron 
administration. However, using finer mental psychometric and 
psychomotor tests, subclinical alterations have been detected 
that are not identifiable in routine physical examinations, 
even after adequately correcting iron deposits. Some authors 
have outlined the importance of iron in the brain’s normal 
functioning, having described the existence of a correlation 
between iron levels and cognitive capacity.32
Two great population studies, The Health and Nutrition 
Examination Survey (NHANES III) and the Third Report 
on Nutrition Monitoring in the United States (1988–1991),32 
  evidenced a prevalence of IDA of 3% to 15% in children 
between 1 and 3 years of age. Several causes are responsible: on 
the one hand, the low socioeconomic level that determines inad-
equate diets in many cases; on the other hand, in this age group, 
children are incorporated into a “normalized diet together with 
adults” in which iron-supplemented foods stop being adminis-
tered, and on occasions, deficient diets are implemented.
Prevention and treatment of ID in 
children
For primary prevention, almost all clinical guidelines rec-
ommend supplementation in asymptomatic infants between 
6 and 12 months of age at risk for ID.33
Iron-fortified diets improve hematologic parameters 
in populations, as evidenced in a previously mentioned 
historical series assessed in the United States following the 
implementation of Special Supplemental Food Program 
for Women, Infants, and Children (WIC) in 1972, which 
dramatically decreased the prevalence of IDA in the entire 
socioeconomic range of the United States.34 Iron-fortified 
foods can be useful to provide daily doses of this nutrient to 
populations, especially in developing countries.35 However, 
in developed areas, people on iron-poor diets or at risk for 
ID need to be identified and counseled individually.27
Infants considered at risk include those of low socioeco-
nomic status, Africans or African Americans,   immigrants from 
developing countries during the first 2 years of   residency, those 
born preterm and small for gestational age, as well as those 
who did not receive an adequately   supplemented continuation 
formula. Likewise, health education is recommended for 
the promotion of breastfeeding, as well as to promote iron-
fortified diets in infants and pregnant women.
For secondary prevention, the US Preventive Task Force 
recommends screening pregnant women for ID,36 but there 
is not enough evidence to make recommendations in favor 
or against routine screening in asymptomatic people at any 
other age.37 Infants with one or more risk factors should be 
subject to screening for ID. The introduction of cow’s milk 
in the first year of life and the socioeconomic level are factors 
to take into consideration in the investigation.
Screening during the first year of life is carried out 
between 9 and 12 months of age. Especial consideration 
must be given to preterm infants and those small for gesta-
tional age, whose screening must be conducted at 6 months 
and every 3 months in those not receiving iron supplements 
or iron-supplemented formulas. After 12 months, any   at-risk 
infant should be studied at the slightest doubt about symptoms. 
A positive result in screening tests requires confirmation 
with an iron-treatment trial. The ideal screening tool should 
allow ID to be discovered before the development of subse-
quent anemia or associated deficits. The usual screening test 
has been hemoglobin or hematocrit levels; however, these 
parameters are altered only when ID is very severe. Ferritin 
levels, transferrin saturation index, and erythrocytic proto-
porphyrin levels have greater sensitivity and specificity, but 
because their cost is higher, they are not to be used routinely. 
Out of all these diagnostic tests, erythrocytic protoporphy-
rin levels are more cost-effective, and some clinical studies 
have shown their effectiveness as screening tools in field 
settings.38,39 The validation of hematofluorometry methods 
for estimating erythrocytic protoporphyrin combined with 
hemoglobin levels shows a promising future in screening 
strategies. Obtaining the RDW, combined with hemoglobin 
levels, may be an option in cases where protoporphyrin cannot 
be measured. The elevation of RDW is an early indicator of ID, 
and almost all blood analyses provide it automatically along 
with   hemoglobin. Other markers, such as transferrin soluble 
receptor or content of erythrocytic hemoglobin, are currently 
being evaluated. In areas where it is not possible to carry out a 
complete blood count or an evaluation of   erythrocytic proto-
porphyrin, screening with hemoglobin must not be   abandoned. 
Moreover, hemoglobin continues to be the parameter that 
determines the cut-off point for   different ages, genders, and 
even races, in terms of   definition of anemia.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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After detecting IDA, it is recommended to carry out an iron 
stores filling test, which implies treatment with iron for 1 month, 
repeating the hemoglobin test, and if an increase of 1 g/dL 
or greater is observed in the values of hemoglobin (or three 
points in the hematocrit), the existence of ID can be concluded 
(even if the baseline hemoglobin is practically normal). This 
treatment with iron supplements is administered in children at a 
dose of 3–6 mg/kg/day of elemental iron, distributed in several 
doses. If ID prevails after the adequate treatment with oral iron, 
a complete etiological study in all cases is indicated.
ID in pregnant women
During pregnancy, women need iron and folic acid for their 
own metabolism and that of the fetus. Anemia, ID, and folate 
deficiency increase the risk of neural tube defects, preterm 
births, and low birth weight. Adequate iron levels in the mother 
are essential for preventing ID in the fetus. Several studies 
have shown that joint supplementation of iron and folic acid 
during pregnancy significantly reduces preterm births and early 
neonatal mortality, one of the main causes of infant mortality 
in developing countries, compared with the administration 
of folic acid alone.40–42 A comprehensive review of the use of 
iron and folic acid supplements in pregnancy suggests that the 
reduction of anemia is similar following daily or weekly dosing 
regimens, which means that iron dosing regimens in pregnancy 
should be revised in order to continue achieving the desired 
effect while minimizing side effects.43 Women with established 
IDA should receive iron supplements additionally to the usual 
recommended dose (see section on treatment). Intolerance to 
the different oral iron preparations is not uncommon, especially 
during gestation, a period in which the gag reflex is increased. 
In these cases, the need for an intravenous treatment must be 
individualized for each patient (likely starting from the second 
or third trimester of pregnancy).
IDA in the elderly
Anemia is very frequent among the elderly; hence, numerous 
studies have been conducted in order to attempt to define 
if there are different ranges of normality in different age 
groups that would enable selection of those patients who 
would require a clinical assessment.44 Thus, in those over 
85 years of age, using the WHO definition of anemia, up to 
26% of men and 20% of women would be suitable for an 
etiological study.45 Anemia in the elderly is clinically very 
relevant and several studies have linked it to an increase in 
overall morbidity, a higher rate of Alzheimer’s disease, worse 
results in quality of life scores, a greater number of hospital 
admissions, and a higher overall mortality.46,47
On the importance of nutritional deficiency as a cause 
of anemia in the elderly, the study NHANES III suggested 
its involvement in one-third of the patients over 65 years of 
age.48 Most of these cases were due to ID, including chronic 
losses, although a percentage was associated with folate or 
vitamin B12 deficiencies. Other significant etiologies of 
anemia in the elderly that should be taken into consideration 
in the differential diagnosis of IDA are anemia due to chronic 
disorders (including the very common presence of chronic 
renal disease) and myelodysplastic syndromes.
In conclusion, the high prevalence of anemia in elderly 
patients (higher in men than in women) can be influenced by 
using cut-off points that are too high when it comes to defining 
anemia. However, anemia is more frequent in patients over 
65 years of age, and much more in those over 85 years of 
age (“the oldest old”) due to all factors presented above. In 
any case, it is very important to keep in mind that other very 
important conditions, such as tumors, are usually involved in 
the development of IDA in the elderly. The diagnostic and 
therapeutic approach must be as usual; nonetheless, the pos-
sibility of dietary deficiency as a cause or promoting factor 
should be considered on an individual basis.
Deficiencies in patients with dietary 
restrictions: patients with celiac disease
Numerous patients, for several reasons, follow a restricted diet 
more or less strictly: diets for allergic patients, ketogenic diets, 
diets through probes, tubes or ostomies, vegetarian diets, 
and macrobiotic diets, for example. We will focus on celiac 
disease. In untreated patients, the absorption of iron and 
other nutrients is frankly compromised48,49 and usually causes 
multiple deficiencies, such as iron, folates, and calcium. 
  Malabsorption of fat-soluble vitamins (ADEK), carbohy-
drates, fats, and other micronutrients can occur if more distal 
segments of small bowel are affected. Deficits in vitamins 
B12 and B6, as well as zinc, selenium, and copper, have also 
been described. Once the diet has been established, absorption 
normalizes. However, some studies suggest that even celiac 
patients who are “strict compliers” with a gluten-free diet 
can have dietary deficiencies, derived from the imbalance 
between proteins, carbohydrates, and fats, which, in turn, 
result in deficits of different micronutrients.48,49 At the point 
of diagnosis, it is usually advisable, apart from an adequate 
gluten-free diet and correcting the confirmed deficiencies, 
to prescribe gluten-free vitamin supplements. Changing and 
combining cereals and flours may provide more quality to the 
diet. Thus, as an alternative to wheat, amaranth, buckwheat, 
millet, whole rice or brown rice, quinoa, soy, or Indian rice can International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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be used. Another substitute for wheat available is millet flour. 
When it is uncertain whether the patient’s diet is sufficiently 
balanced, it is reasonable to complement it with the referred 
gluten-free multivitamin complexes.50
IDA in developing countries
It is in this scenario where anemia due to poor iron dietary intake 
is most relevant. In many of these countries, the prevalence of 
malnutrition is considerable, and iron intake is often inadequate. 
The WHO has estimated that, in developing countries, IDA is 
the third cause of disability-adjusted life years lost in 15- to 
44-year-old women. For men in this age group, anemia con-
sistently ranks in the top 10 causes of morbidity.38 Infants and 
women of childbearing age are mostly affected. Malnutrition, 
with the consequential ID, is found in up to 53% of conditions 
that cause the greatest infant morbidity and mortality. The 
purely nutritional problem is aggravated in these countries 
because they usually do not implement programs for iron 
fortification of feeding formulas. As we indicated previously, 
several studies have shown that iron has a direct influence on 
birth weight, as well as on the incidence of preterm births, 
although the designs of these studies have been criticized and 
the implications for clinical daily practice are limited.51
We must remember that although poor iron intake is the main 
cause of anemia in developing countries, numerous factors may 
be associated and represent the etiology or promoting factors 
of anemia in these populations (Table 6). Hence, the control of 
parasitic infections in developing countries is of considerable 
importance in public health. Mild infections with multiple para-
sitic species have been associated with an increased frequency 
of anemia in most developing countries.52 Hookworm and 
Schistosoma spp. infections are leading causes of anemia in these 
countries and co-administration of drugs with multiple courses 
of treatment has been an effective strategy.53 Nonetheless, the 
problem cannot be overcome by preventive chemotherapy alone. 
In order to achieve a sustainable control of parasitic infections 
and prevention of anemia, access to safe and effective drugs, 
complemented with health education, improvements in water 
supply, and adequate sanitation are necessary.54
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